HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anemia as a risk factor for kidney function decline in individuals with heart failure.

Abstract
Chronic kidney disease (CKD), anemia, and declining kidney function are recognized as risk factors for adverse outcomes in patients with heart failure. This analysis was conducted to evaluate whether anemia is a risk factor for kidney function decrease in patients with heart failure. Data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized trial of enalapril versus placebo in patients with ejection fractions <or=35%, were analyzed. After randomization, creatinine measurements were taken at 2 weeks, 6 weeks, 4 months, and every 4 months thereafter. The glomerular filtration rate (GFR) was estimated using the Modification of Diet in Renal Disease Study (MDRD) equation, and GFR slope was calculated. "Rapid decrease" was defined as a decrease in the GFR of >or=6 ml/min/1.73 m(2)/year. Anemia was defined as baseline hematocrit <36%. Multivariate logistic regression weighted by the number of GFR assessments was used to test the relation between anemia and rapid decrease. We also evaluated whether CKD (baseline GFR </=60 ml/min/1.73 m(2)) modified the relation between anemia and rapid decrease. In the 6,360 subjects, the mean age was 59 years, 31% had CKD, and 6% had anemia. Median follow-up was 2 years. In multivariate analysis, anemia was associated with a 1.30 increased odds (95% confidence interval 1.18 to 1.45) of rapid decrease in GFR. In subjects with CKD, anemia was associated with a 1.71 increased odds (95% confidence interval 1.43 to 2.05) of rapid decrease, while in subjects without CKD, anemia was associated with a 1.16 increased odds (95% confidence interval 1.03 to 1.31) of rapid decrease (p for interaction <0.001). In conclusion, anemia is associated with a rapid decrease in kidney function in patients with heart failure, particularly in those with underlying CKD.
AuthorsNisha Bansal, Hocine Tighiouart, Daniel Weiner, John Griffith, Panagiotis Vlagopoulos, Deeb Salem, Adeera Levin, Mark J Sarnak
JournalThe American journal of cardiology (Am J Cardiol) Vol. 99 Issue 8 Pg. 1137-42 (Apr 15 2007) ISSN: 0002-9149 [Print] United States
PMID17437743 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Angiotensin-Converting Enzyme Inhibitors
  • Placebos
  • Enalapril
  • Creatinine
Topics
  • Anemia (complications)
  • Angiotensin-Converting Enzyme Inhibitors (therapeutic use)
  • Cardiac Output, Low (complications, drug therapy)
  • Chronic Disease
  • Cohort Studies
  • Creatinine (blood)
  • Diabetes Complications (physiopathology)
  • Double-Blind Method
  • Enalapril (therapeutic use)
  • Female
  • Follow-Up Studies
  • Glomerular Filtration Rate (physiology)
  • Hematocrit
  • Humans
  • Hypertension (complications)
  • Kidney (physiopathology)
  • Kidney Diseases (physiopathology)
  • Male
  • Middle Aged
  • Placebos
  • Risk Factors
  • Stroke Volume (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: